MedTrace Logo

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

NCT02408042 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2017-06-27

No results posted yet for this study

Summary

To determine the recommended phase 2 dose of chemotherapy in combination with Pembrolizumab in subjects with advanced lymphoma and determine the complete response rate.

Conditions

  • Lymphoma
  • Hodgkin's Lymphoma
  • Non-hodgkin's Lymphoma

Interventions

DRUG

Pembrolizumab

DRUG

Etoposide

DRUG

Ifosfamide

DRUG

Mesna

DRUG

Carboplatin

DRUG

Brentuximab vedotin

DRUG

Rituximab

Sponsors & Collaborators

  • Western Regional Medical Center

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02408042 on ClinicalTrials.gov